Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week

Core Insights - Evaxion A/S is a clinical-stage TechBio company focused on developing AI-Immunology™ powered vaccines and will present its 2026 milestones at the Biotech Showcase conference in San Francisco from January 12-14, 2026 [1][2] - The company aims to engage with stakeholders and potential business partners during the conference week [2] Company Overview - Evaxion utilizes its proprietary AI platform, AI-Immunology™, to decode the human immune system and create novel immunotherapies for cancer, bacterial diseases, and viral infections [3] - The company has developed a clinical-stage oncology pipeline of personalized vaccines and a preclinical pipeline targeting infectious diseases with significant unmet medical needs [3] - Evaxion is dedicated to transforming patient care through innovative and targeted treatment options [3] Presentation Details - The presentation by CEO Helen Tayton-Martin is scheduled for January 13, 2026, at 2:00 PM PST/11:00 PM CET in the Yosemite C track [3] - Contact information for investor relations is provided for further inquiries [3]